Evergreening's Hidden Toll: How Patent Strategy Is Crowding Out the Cures Medicine Actually Needs

The intellectual property framework governing pharmaceutical innovation was designed to reward discovery and accelerate access to new medicines. Instead, a growing body of evidence suggests it has become a mechanism for entrenching existing revenue streams while genuinely transformative therapies — particularly in gene therapy and rare disease — struggle to attract the capital they require. Understanding how patent strategy shapes the biotech pipeline is no longer an academic exercise; it is a clinical urgency.

A System Built for Innovation, Repurposed for Protection

Under US patent law, a novel drug compound may be protected for twenty years from the date of filing. In theory, this window is sufficient to allow a manufacturer to recoup research and development expenditures before generic competition enters the market. In practice, the timeline rarely works as cleanly as the statute implies. Drug development is slow, regulatory review consumes years, and the effective market exclusivity period — the time a company actually has to sell its product without competition — is often far shorter than the raw patent duration suggests.

This compression created an incentive structure that few legislators anticipated when the Hatch-Waxman Act was signed in 1984. Rather than accept the narrowing window and redirect capital toward next-generation compounds, many manufacturers discovered that the patent system itself could be extended through a practice now widely described as evergreening: the filing of secondary patents on minor modifications to an existing drug — a new salt form, an altered dosing schedule, a modified-release coating, a pediatric formulation — each capable of adding years, sometimes decades, of additional exclusivity.

The result is a pharmaceutical landscape in which the most commercially successful molecules are surrounded by dense thickets of overlapping intellectual property claims, making generic entry legally treacherous long after the original compound patent has expired.

The Arithmetic of Incremental Investment

From a purely financial standpoint, the logic of incremental innovation is difficult to dispute. Developing a reformulation of a drug with an established safety profile costs a fraction of what it takes to bring a novel therapeutic modality from target identification through Phase III. The regulatory pathway is shorter, the clinical risk is lower, and the commercial baseline — an existing prescriber relationship and patient population — is already established.

Contrast that calculus with what it takes to advance a gene therapy program. A single-administration curative approach targeting a rare monogenic disorder may require a decade of preclinical work, bespoke manufacturing infrastructure, and a clinical development program that, by definition, enrolls small patient populations generating limited statistical power. The upfront capital requirement is enormous. The probability of regulatory success is uncertain. And the commercial model — charging a one-time price for a durable cure — remains deeply contested by payers.

When institutional capital faces a choice between funding the fourteenth reformulation of a blockbuster molecule and the first-in-class gene therapy for a disease affecting forty thousand Americans, the patent system's incentive gradient quietly points toward the former. The reformulation will almost certainly generate a return. The gene therapy might change medicine — or it might not survive its pivotal trial.

Case Studies in Strategic Exclusivity

The insulin market offers perhaps the most thoroughly documented illustration of evergreening's consequences. Researchers at Harvard Medical School published an analysis in 2021 documenting more than eight hundred patents filed on insulin products by three major manufacturers between 2014 and 2019. The overwhelming majority covered delivery devices, formulations, and dosing concentrations rather than the active molecule itself. The practical effect was to extend effective exclusivity well beyond what the original compound patents would have permitted, keeping list prices elevated and biosimilar entry legally complicated even as patients rationed doses.

The pattern recurs across therapeutic categories. Extended-release formulations of psychiatric medications have been the subject of repeated antitrust scrutiny. Biologic manufacturers have used device patents — on auto-injectors and prefilled syringes — to construct exclusivity timelines that persist years after the biologic compound itself has lost protection. In each case, the legal strategy was technically valid. In each case, the downstream effect on patient access was measurable and negative.

Within the gene therapy space, the dynamic manifests differently but with comparable consequences. Patent thickets surrounding foundational delivery technologies — particularly adeno-associated virus serotypes and CRISPR-related intellectual property — have generated extensive litigation between academic institutions and commercial developers. The University of California and the Broad Institute spent years in patent interference proceedings over foundational CRISPR claims. Whatever the legal merits of each position, the practical effect of prolonged uncertainty was to complicate licensing negotiations and slow the downstream development of clinical programs that depended on access to the underlying technology.

What Reform Could Look Like

The policy conversation around pharmaceutical patents has intensified considerably in recent years. The Inflation Reduction Act of 2022 introduced Medicare drug price negotiation for a limited set of products, creating modest pressure on manufacturers to justify pricing relative to clinical benefit. But the legislation did not directly address the secondary patent problem, and the number of drugs subject to negotiation in the near term remains small relative to the overall market.

More structurally ambitious proposals have circulated in academic and policy circles for years. Some researchers have advocated for stricter patentability standards at the US Patent and Trademark Office — specifically, a more demanding application of the nonobviousness requirement to secondary pharmaceutical patents. Under current practice, a new salt form of an existing compound may satisfy the novelty requirement without demonstrating meaningful therapeutic improvement. A higher bar would require applicants to show that a modification produces a genuine clinical advance, not merely a chemical variation.

Others have proposed prize-based funding mechanisms as a complement to the patent system, particularly for therapeutic areas where market incentives are structurally insufficient. Under such a model, governments or multilateral bodies would offer substantial financial awards for demonstrated clinical breakthroughs in neglected disease categories, decoupling the reward for innovation from the monopoly pricing that exclusivity currently enables.

Neither approach is without complications. Stricter patentability standards require administrative capacity and legal consistency that are difficult to guarantee. Prize mechanisms require policymakers to correctly identify which innovations deserve reward before the market has revealed their value — a prediction that regulators have historically struggled to make reliably.

The Pipeline That Isn't Being Built

What is perhaps most difficult to measure — and therefore easiest to ignore — is the opportunity cost of the current system. The gene therapies that are not being developed, the novel mechanisms that are not being pursued, the patient populations that are not being studied: these absences do not appear in any financial filing or congressional testimony. They exist only as a counterfactual, a pipeline that could exist if the incentive structure pointed differently.

For the researchers and clinicians working in areas of genuine unmet need — pediatric neurological disease, ultra-rare metabolic disorders, monogenic conditions affecting small populations — the gap between what the science makes possible and what the capital markets are willing to fund is a daily professional reality. Patent strategy did not create that gap alone. But it has done a great deal to widen it.

The question facing US policymakers, investors, and the scientific community is not whether the patent system should exist. It should. Intellectual property protection remains a necessary condition for private investment in pharmaceutical research. The question is whether the system as currently practiced is producing the outcomes it was designed to generate — and whether the patients waiting for genuinely new medicines can afford to wait while that question goes unanswered.